Homology Medicines, Inc.(FIXX)

Description: Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

---

Keywords: Medicine Biology Molecular Biology Rare Diseases Eye Gene Therapy Bone Medical Genetics Dystrophy Bone Marrow Applied Genetics Genetic Diseases Gene Delivery Hematopoietic Stem Cell Genetic Disorder Rare Genetic Diseases Phenylketonuria Pku Rare Genetic Disease Peripheral Nervous System Leukodystrophy

---

Home Page: www.homologymedicines.com

FIXX Technical Analysis

One Patriots Park
Bedford, MA 01730
United States
Phone: 781 301 7277

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)